Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v13.i12.2038

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5565)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

309

WORD

HTML

2113

Figures (1-1)

232

Tables (1-1)

208

Sum=2945

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

399

Download

835

Sum=1234

Publishing Process of This Article

Item

Count

Browse

391

Download

995

Sum=1386

Dec 15, 2021 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2038-2049
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2038

Open in New Tab Full Size Figure Download Figure

Figure 1 Evolution of clinical trials and real-world data for sorafenib and lenvatinib. AEs: Adverse events; BCLC: Barcelona Clinic Liver Cancer; DCR: Disease control rate; ECOG: Eastern Cooperative Oncology Group; HCC: Hepatocellular carcinoma; ITT: Intent-to-treat population; ORR: Objective response rate; OS: Overall survival; PFS: Progression-free survival; TKI: Tyrosine-kinase inhibitor; TRAE: Treatment-related adverse event; TTP: Time to progression.

Citation: Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049
URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2038.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2038